RxDoctor Payments Data

Solomon Ross, MD

Ophthalmology · Valdosta, GANPI 1548499940

Payments from drug & device makers

$5,120in general payments, 2019–2025

Across 172 payments — averaging $29.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • ANI Pharmaceuticals, Inc.$518
  • Novartis$333
  • Amgen$315
  • Nova Eye, Inc.$236
  • Sight Sciences, Inc.$216
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,92796%
  • Gifts$451%
  • Entertainment$1483%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,120 in reported general payments places this provider in the 70th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$392,963
Medicare patients
772
Services billed
3,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TepezzaTeprotumumab-Trbw14$770,797
RestasisCyclosporine71$74,783
VyzultaLatanoprostene Bunod105$60,976
XiidraLifitegrast26$41,999
SimbrinzaBrinzolamide/Brimonidine Tart84$32,674
LumiganBimatoprost71$29,097
RhopressaNetarsudil Mesylate36$24,672
RocklatanNetarsudil Mesylat/Latanoprost44$21,861
Cyclosporine35$19,026
CombiganBrimonidine Tartrate/Timolol36$18,063
MoxifloxacinMoxifloxacin Hcl527$13,463
MieboPerfluorohexyloctane/Pf18$13,243
Travoprost67$13,162
Brimonidine Tartrate225$12,618
Prednisolone Acetate326$11,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTepezza$315$770,79714 claims
AbbVieRestasis, Lumigan, Combigan, Alphagan P$101$127,333192 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$88$116,218149 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$148$46,53380 claims
AlconSimbrinza$2,114$32,67484 claims
Sun Pharmaceutical Industries Inc.Cequa$137$9,00812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →